アピキサバン 化學(xué)特性,用途語(yǔ),生産方法
用途
アピキサバン（Apixaban、開(kāi)発コードBMS-562247-01）は、血栓塞栓癥の治療?予防に用いられる、経口投與が可能な抗凝固剤の1つである。商品名エリキュース。血液凝固因子の1種であるXa因子を薬剤そのものが阻害する、直接X(jué)a因子阻害薬（英語(yǔ)版）に分類(lèi)される。また、第Xa因子は酵素なので、酵素阻害剤に分類(lèi)される薬剤でもある。なお、肝代謝型（肝排泄型）の薬剤としても知られる。
効能
抗凝固薬, 抗血栓薬, 第Xa因子阻害薬
商品名
エリキュース (ブリストル?マイヤーズスクイブ)
説明
Eliquis (apixaban), a direct inhibitor of factor Xa (FXa), was approved by the European Commission on May 18, 2011 for prevention of venous thromboembolic events (VTE) in adult patients who have undergone elective hip or knee replacement surgery. Apixaban (357.5 mg) also prevents thrombus formation without inducing adverse bleeding events in a porcine model of aortic heterotopic valve replacement. Formulations containing apixaban have been used to prevent blood clot formation in patients with atrial fibrillation.
來(lái)歴
Apixaban is an oral anticoagulant jointly developed by Bristol-Myers Squibb (BMY) and Pfizer (PFE) for the prevention of stroke and systemic embolism in patients with atrial fibrillation. It is marketed under the brand name Eliquis. The drug was approved for use by the European Medicines Agency in 2011 and by the U.S. Food and Drug Administration in 2012.
使用
Apixaban is a highly selective, reversible inhibitor of Factor Xa with Ki of 0.08 nM and 0.17 nM in human and rabbit, respectively.
定義
ChEBI: A pyrazolopyridine that is 7-oxo-4,5,6,7-tetrahydro-1H-pyrazolo[3,4-c]pyridine-3-carboxamide substituted at position 1 by a 4-methoxyphenyl group and at position 6 by a 4-(2-oxopiperidin-1-yl)phenyl group. It is used for the
prevention and treatment of thromboembolic diseases.
薬物動(dòng)態(tài)學(xué)
The maximum plasma concentration (Cmax) of apixaban occurs 3–4 h after oral administration. The absorption of apixaban appears to occur primarily in the small intestine and decreases progressively throughout the gastrointestinal tract. Compared with oral administration, the bioavailability of 2.5 mg of apixaban solution was approximately 60% and 84% lower when released in the distal small bowel and ascending colon, respectively. For oral doses up to 10 mg, the absolute bioavailability of apixaban is~50%, resulting from the incomplete absorption and first-pass metabolism in the gut and liver[1].
臨床応用
Apixaban is an oral anticoagulant with highly selective inhibition
of factor Xa. It was approved by the European Medicines
Agency (EMA) for the treatment of venous thromboembolic events
and first marketed in Germany under the brand name Eliquis in
June 2011. Apixaban was co-developed by Bristol-Myers Squibb
and Pfizer and represents the first approved drug for this indication
since warfarin over 50 years ago.
副作用
Possible side effects of Apixaban are: bleeding gums, nosebleeds, heavy vaginal bleeding
, red, pink, or brown urine; red or black, tarry stools; coughing or spitting up blood or a substance that looks like coffee grounds; swelling or joint pain, headache, rash, chest pain or tightness in the chest, swelling of the face or tongue, trouble breathing, wheezing. Feeling dizzy or fainting.Apixaban prevents your blood from clotting properly, so if you get a cut or injury, it may take longer than usual for the bleeding to stop. This medication may also cause you to bruise or bleed more easily.
參考文獻(xiàn)
https://en.wikipedia.org/wiki/Apixaban
https://www.drugbank.ca/drugs/DB06605[1] Wonkyung Byon. “Apixaban: A Clinical Pharmacokinetic and Pharmacodynamic Review.” Clinical Pharmacokinetics 58 10 (2019): 1265–1279.
アピキサバン 上流と下流の製品情報(bào)
原材料
準(zhǔn)備製品